Avantor Inc (FRA:AVG)
€ 20.2 0.4 (2.02%) Market Cap: 13.71 Bil Enterprise Value: 18.45 Bil PE Ratio: 57.05 PB Ratio: 2.76 GF Score: 77/100

Avantor Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript

Mar 22, 2022 / 06:15PM GMT
Release Date Price: €30.6 (-1.92%)
Paul Richard Knight
KeyBanc Capital Markets Inc., Research Division - MD & Senior Analyst

Hi. This is Paul Knight at KeyBanc Capital Markets. I'm the life science analyst. When -- similar format today, there will be a room for questions on the chat that you could submit on your screen or e-mail myself at paul.r.knight.

I think Tom wants to make some opening comments, and also today, Gerard Brophy, who's Head of the bioproduction unit at Avantor. As many of you know, we've been doing a lot of work in this area over the past several years. It's certainly a high-growth area and been a focus of M&A for Avantor. So an exciting year, many years ahead, we believe, in terms of biologic production in the industry.

But Tom, I'll let you start with some opening remarks, and I know Ger wants to -- will do the same.

Thomas A. Szlosek
Avantor, Inc. - Executive VP & CFO

Okay. Appreciate it. Thanks, Paul. So I just want to remind the attendees a little bit about Avantor and also reiterate our '22 financial guidance. So we're an $8 billion

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot